Translational studies will consist of comparing efficacy and toxicity to the dosimetry of [177Lu]Lu-PSMA-I&T in normal tissues and tumor lesions, as well as the biomarkers obtained from blood or tumor tissue samples. This evidence concerns the gene FOLH1 and neoplasm.